China-based liquid biopsy testing service provider Beijing Gene+ Technology has raised RMB200m ($30m) in a series A round led by genome sequencing business BGI, China Money Network reported today.
The corporate was joined by venture capital and private equity fund manager Green Pine Capital Partners and Shanghai Huoshanshi Capital.
Established in April 2015, Beijing Gene+ offers data analytics for precision medicine. It also provides gene testing for early cancer detection and prevention, claiming to have served several thousand patients across around 100 hospitals.
The deal marks the largest round for a startup of its kind in China, according to local media reports. Beijing Gene+ has not revealed details about what it intends to do with the cash and has not disclosed whether it has raised any previous funding.